Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1141825

registered interest
date	24/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	MMR Vaccine
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that parents and carers are provided with accurate information on the benefits and risks of the MMR vaccine.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	281668
answer	answer is ministerial correction date of answer 09/09/2019 answer text <p>The National Health Service website has a dedicated page on the measles, mumps and rubella (MMR) vaccine, which can be found at the following link:</p><p><a href="https://www.nhs.uk/conditions/vaccinations/mmr-vaccine/" target="_blank">https://www.nhs.uk/conditions/vaccinations/mmr-vaccine/</a></p><p>In addition, Public Health England provides information on the benefits and risks of the MMR vaccine to the public using NHS branded leaflets, some of which are available in multiple languages. The leaflets address common questions about the MMR vaccine. In addition to parents and carers this information is designed for use by schools, healthcare centres, accident and emergency departments, hospital wards, walk-in centres and general practices.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 09/09/2019 14:56:52 answering member 4380 label Biography information for Jo Churchill
tabling member	1522 label Biography information for Adam Holloway

1141362

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Measles
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what guidance his Department has published on distinguishing between rashes caused by the measles vaccine and those arising from the wild strain of measles.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	280995
answer	answer is ministerial correction date of answer 05/08/2019 answer text <p>While post vaccine rash and fever is generally mild, distinguishing from wild-type measles is not based on clinical examination, rather it is based on a combination of laboratory analysis, information on the timing of vaccine and epidemiological information. The national measles guidelines describe the management and investigation of suspected cases of measles, and is available to view at the following link:</p><p><a href="https://www.gov.uk/government/publications/national-measles-guidelines" target="_blank">https://www.gov.uk/government/publications/national-measles-guidelines</a></p><p>Statistics on confirmed measles cases are reported by vaccination status and are available at the following link:</p><p><a href="https://www.gov.uk/government/publications/measles-mumps-and-rubella-lab-confirmed-cases-in-england-2019" target="_blank">https://www.gov.uk/government/publications/measles-mumps-and-rubella-lab-confirmed-cases-in-england-2019</a></p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 280996 question first answered 05/08/2019 11:32:33 answering member 4380 label Biography information for Jo Churchill
tabling member	1522 label Biography information for Adam Holloway

1141363

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Measles
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that statistics on the infection rate for measles do not include people who have received the live measles vaccine and contracted a measles-like rash and fever.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	280996
answer	answer is ministerial correction date of answer 05/08/2019 answer text <p>While post vaccine rash and fever is generally mild, distinguishing from wild-type measles is not based on clinical examination, rather it is based on a combination of laboratory analysis, information on the timing of vaccine and epidemiological information. The national measles guidelines describe the management and investigation of suspected cases of measles, and is available to view at the following link:</p><p><a href="https://www.gov.uk/government/publications/national-measles-guidelines" target="_blank">https://www.gov.uk/government/publications/national-measles-guidelines</a></p><p>Statistics on confirmed measles cases are reported by vaccination status and are available at the following link:</p><p><a href="https://www.gov.uk/government/publications/measles-mumps-and-rubella-lab-confirmed-cases-in-england-2019" target="_blank">https://www.gov.uk/government/publications/measles-mumps-and-rubella-lab-confirmed-cases-in-england-2019</a></p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 280995 question first answered 05/08/2019 11:32:33 answering member 4380 label Biography information for Jo Churchill
tabling member	1522 label Biography information for Adam Holloway

1141364

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	MMR Vaccine: Side Effects
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that (a) body inclusion encephalitis and (b) other adverse events experienced after a measles vaccine are identified in a timely way by healthcare professionals.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	280997
answer	answer is ministerial correction date of answer 05/08/2019 answer text <p>The safety of all the United Kingdom’s vaccination programmes is of paramount importance. Any serious side effects are extremely rare, and the large majority of side effects are mild and transient, such as sore arms, headaches and tiredness. We would recommend that all eligible children are vaccinated, as any potential risk of side effects is far outweighed by the benefits of vaccination.</p><p>Healthcare professionals have access to a range of materials, such as ‘Immunisation against infectious disease: the green book’ and Patient Group Directions to support their decision-making in the case of any suspected adverse effects.</p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) operates the ‘Yellow Card Scheme’, which is vital in helping the MHRA monitor the safety of all healthcare products in the UK. This system allows for reporting of any potential adverse events for all medicines, including vaccines, with guidance for healthcare professionals, patients and the public on how to use the scheme.</p><p>In addition, Public Health England (PHE) offers diagnostic services for suspected cases of encephalitis, which is a notifiable condition. Under statutory duty, cases must be reported by healthcare professionals to PHE’s local Health Protection Teams. This can be viewed at the following link:</p><p><a href="https://www.gov.uk/government/collections/notifications-of-infectious-diseases-noids" target="_blank">https://www.gov.uk/government/collections/notifications-of-infectious-diseases-noids</a></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 05/08/2019 11:34:01 answering member 4380 label Biography information for Jo Churchill
tabling member	1522 label Biography information for Adam Holloway

1141380

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	MMR Vaccine: Safety
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to maintain and improve pharmacovigilance in relation to the MMR vaccine.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	280998
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>As with all vaccines and medicines, the safety of the Measles, Mumps and Rubella (MMR) vaccine remains under continual review by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA uses all available sources of evidence in pharmacovigilance, including regular review of suspected adverse reactions submitted through the Yellow Card Scheme, data from clinical and epidemiological studies, the medical literature and information from pharmaceutical companies and other worldwide regulatory authorities. The MHRA’s processes and data analysis systems are regularly evaluated to ensure optimal performance in monitoring the safety of vaccines and medicines.</p><p>The balance of benefits and risks of MMR vaccine remains overwhelmingly favourable.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:35:38 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1522 label Biography information for Adam Holloway

1141381

registered interest
date	23/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	MMR Vaccine
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure (a) transparency and (b) accountability in the process of manufacturing the MMR vaccine.
tabling member constituency	Gravesham
tabling member printed	Adam Holloway
uin	280999
answer	answer is ministerial correction date of answer 25/07/2019 answer text <p>Two Measles, Mumps and Rubella (MMR) vaccines are licensed for use in the United Kingdom: M-M-RVaxPro and Priorix. Both vaccines are on the National Health Service’s routine immunisation schedule. The quality, safety and efficacy of both M-M-RVaxPro and Priorix have been evaluated before they were given a Marketing Authorisation in Europe, and the Marketing Authorisation Holder for each vaccines is legally required to submit periodic safety update reports to the regulator, which are documents intended to provide an evaluation of the risk-benefit balance of a medicinal product at defined time points after its authorisation. The sites at which the products are manufactured are also required to undergo periodic inspections to ensure that they comply with Good Manufacturing Practices. Each batch of vaccines is tested by an official medicines control laboratory (OMCL). OMCL testing is independent of and in addition to the manufacturer’s testing. These procedures ensure that the MMR vaccines available in the UK are safe and efficacious and that the manufacturers/Marketing Authorisation holders are held accountable for their products.</p><p>A European Public Assessment Report (EPAR) for M-M-RVaxPro is available at the following link:</p><p><a href="https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf" target="_blank">https://www.ema.europa.eu/en/documents/scientific-discussion/m-m-rvaxpro-epar-scientific-discussion_en.pdf</a></p><p>Priorix was approved before public assessment reports were a requirement. The EPAR for M-M-RVaxPro contains a general summary of the manufacturing information that was provided during the assessment process; however, the specific details of the manufacturing process are confidential.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 25/07/2019 16:38:57 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1522 label Biography information for Adam Holloway